# Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

> **NCT04191135** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 462 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Olaparib
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04191135
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2022-12-15
- **Final completion:** 2025-11-26
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04191135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04191135, "Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04191135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*